Objective: To perform an evidence-based review of the safety and efficacy of botulinum
neurotoxin (BoNT) in the treatment of adult and childhood spasticity. Methods: A literature …

Botulinum neurotoxins are formulated biologic pharmaceuticals used therapeutically to treat
a wide variety of chronic conditions, with varying governmental approvals by country. Some …

A group of clinicians from across Europe experienced in the use of botulinum toxin type A for
the treatment of spasticity following acquired brain injury gathered to develop a consensus …

Background Between 50 per cent and 70 per cent of stroke patients have ongoing upper
limb functional limitations. Upper limb spasticity may contribute to reduced function, pain and …

This meta‐analysis evaluated the frequency of neutralizing antibody (nAb) conversion with
onabotulinumtoxinA (BOTOX®; Allergan) across five studied indications. The analysis was …

Poststroke hemiparesis, together with abnormal muscle tone, is a major cause of morbidity
and disability. Although most hemiparetic patients are able to reach different ambulatory …

Spasticity is a physiological consequence of an insult to the brain or spinal cord, which can
lead to life-threatening, disabling and costly consequences. This typically occurs following …

Botulinum toxin type-A (BoNT-A) has emerged as a key therapeutic agent for the
management of spasticity. This paper presents a comprehensive bibliometric and visual …

Though the formation of neutralizing antibodies (NAbs) during treatment with botulinum
neurotoxin is rare, their presence may nonetheless affect the biological activity of botulinum …

Spasticity is a common symptom observed after pyramidal system lesion. The treatment of
spasticity has considerably changed during last years, notably with the generalization of …